BIRONZO, Paolo
 Distribuzione geografica
Continente #
NA - Nord America 5.783
EU - Europa 3.384
AS - Asia 2.897
OC - Oceania 103
SA - Sud America 53
AF - Africa 28
Continente sconosciuto - Info sul continente non disponibili 15
Totale 12.263
Nazione #
US - Stati Uniti d'America 5.643
CN - Cina 1.260
IT - Italia 1.118
SG - Singapore 549
IE - Irlanda 365
SE - Svezia 354
GB - Regno Unito 268
JP - Giappone 243
DE - Germania 210
FR - Francia 210
IN - India 155
ES - Italia 141
TW - Taiwan 116
HK - Hong Kong 102
UA - Ucraina 102
CA - Canada 101
AU - Australia 93
KR - Corea 90
TR - Turchia 89
FI - Finlandia 86
PL - Polonia 83
VN - Vietnam 83
ID - Indonesia 80
AT - Austria 76
NL - Olanda 63
CH - Svizzera 46
BE - Belgio 44
GR - Grecia 38
RU - Federazione Russa 38
MX - Messico 35
BR - Brasile 22
DK - Danimarca 18
RO - Romania 17
MY - Malesia 16
JO - Giordania 15
PT - Portogallo 15
SA - Arabia Saudita 15
IR - Iran 14
TH - Thailandia 14
HR - Croazia 13
HU - Ungheria 13
IL - Israele 13
NO - Norvegia 13
PH - Filippine 12
SI - Slovenia 11
NZ - Nuova Zelanda 10
PK - Pakistan 10
CL - Cile 9
EG - Egitto 9
NG - Nigeria 8
RS - Serbia 8
AP - ???statistics.table.value.countryCode.AP??? 7
AR - Argentina 7
BA - Bosnia-Erzegovina 7
CO - Colombia 6
CZ - Repubblica Ceca 6
LT - Lituania 6
PE - Perù 5
BG - Bulgaria 4
EU - Europa 4
MA - Marocco 4
UZ - Uzbekistan 4
XK - ???statistics.table.value.countryCode.XK??? 4
LV - Lettonia 3
MO - Macao, regione amministrativa speciale della Cina 3
PS - Palestinian Territory 3
SY - Repubblica araba siriana 3
AL - Albania 2
AM - Armenia 2
BY - Bielorussia 2
ME - Montenegro 2
NP - Nepal 2
SV - El Salvador 2
TG - Togo 2
VE - Venezuela 2
ZA - Sudafrica 2
AE - Emirati Arabi Uniti 1
EC - Ecuador 1
ET - Etiopia 1
GT - Guatemala 1
KH - Cambogia 1
MK - Macedonia 1
MM - Myanmar 1
MN - Mongolia 1
PA - Panama 1
PY - Paraguay 1
SK - Slovacchia (Repubblica Slovacca) 1
SN - Senegal 1
TN - Tunisia 1
Totale 12.263
Città #
Chandler 605
Singapore 430
Santa Clara 420
Dublin 356
Fairfield 327
Beijing 265
Turin 238
Ashburn 217
Houston 202
Torino 196
Wilmington 179
Woodbridge 170
Seattle 163
Ann Arbor 157
Redwood City 148
Nyköping 145
Cambridge 144
Shanghai 123
Columbus 117
Guangzhou 96
New York 88
Medford 87
Princeton 81
Jakarta 78
Pisa 75
Milan 72
Tokyo 64
Vienna 64
Dearborn 63
Nanjing 59
Jacksonville 55
Taipei 53
Dong Ket 51
Hangzhou 49
London 49
Central 43
Helsinki 42
San Diego 39
Wuhan 39
Jinan 38
Warsaw 38
Boston 37
Chengdu 37
Boardman 33
Duncan 32
Los Angeles 32
Seoul 32
Sydney 31
Villeurbanne 31
Paris 30
Hebei 27
Brussels 26
Munich 24
Barcelona 23
Fremont 23
Philadelphia 23
Rome 23
Changsha 22
Nuremberg 22
Chicago 21
Mumbai 21
Piemonte 21
Zhengzhou 21
Ottawa 20
San Francisco 20
Amsterdam 19
Dallas 19
Madrid 18
Hsinchu 17
Lappeenranta 17
Toronto 17
Athens 16
Bengaluru 16
Hong Kong 16
Amman 15
Vancouver 15
Hefei 14
Chongqing 13
Xian 13
Atlanta 12
Geneva 12
Manchester 12
Naples 12
Norwalk 12
Perth 12
Washington 12
Falls Church 11
Las Vegas 11
San Jose 11
Upper Marlboro 11
Changchun 10
Handayama 10
Hyderabad 10
Raritan 10
Shenyang 10
Tianjin 10
Brisbane 9
Evanston 9
Kolkata 9
Redmond 9
Totale 7.006
Nome #
Understanding and overcoming the mechanisms of primary and acquired resistance to abiraterone and enzalutamide in castration resistant prostate cancer 1.192
Addressing the unmet need in lung cancer: The potential of immuno-oncology 1.034
Epigenetic prediction of response to anti-PD-1 treatment in non-small-cell lung cancer: a multicentre, retrospective analysis 640
Bromodomain inhibition exerts its therapeutic potential in malignant pleural mesothelioma by promoting immunogenic cell death and changing the tumor immune-environment 473
Immune checkpoint inhibitors for patients with advanced lung cancer and oncogenic driver alterations: results from the IMMUNOTARGET registry 440
Antiandrogen withdrawal syndrome (AAWS) in the treatment of patients with prostate cancer 375
Efficacy of neurokinin-1 receptor antagonists in the prevention of chemotherapy-induced nausea and vomiting in patients receiving carboplatin-based chemotherapy: A systematic review and meta-analysis 336
Moving from histological subtyping to molecular characterization: new treatment opportunities in advanced non-small-cell lung cancer 323
Wnt/IL-1β/IL-8 autocrine circuitries control chemoresistance in mesothelioma initiating cells by inducing ABCB5 311
Clinicopathologic correlates of first-line pembrolizumab effectiveness in patients with advanced NSCLC and a PD-L1 expression of ≥ 50% 277
Targeted next-generation sequencing of cancer genes in advanced stage malignant pleural mesothelioma: a retrospective study. 274
Potential diagnostic and prognostic role of micro-environment in malignant pleural mesothelioma 271
HERTHENA-Lung01, a Phase II Trial of Patritumab Deruxtecan (HER3-DXd) in Epidermal Growth Factor Receptor-Mutated Non-Small-Cell Lung Cancer After Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor Therapy and Platinum-Based Chemotherapy 246
A systematic review and meta-analysis of trials assessing PD-1/PD-L1 immune checkpoint inhibitors activity in pre-treated advanced stage malignant mesothelioma 241
Advanced non-small cell lung cancer in elderly patients: A review 187
Antagonists of growth hormone-releasing hormone (GHRH) inhibit the growth of human malignant pleural mesothelioma 184
Systematic Review of adverse events reporting in clinical trials leading to approval of targeted therapy and immunotherapy 178
Deficiencies in health-related quality of life assessment and reporting: a systematic review of oncology randomized phase III trials published between 2012 and 2016 168
NIBIT-MESO-1: Limitations and clinical perspectives in MPM treatment testing an immune checkpoint blockade combination in a single-arm study 144
C28Sequencing cabazitaxel and new generation hormonal treatments in metastatic castration resistant prostate cancer patients after first line docetaxel: a retrospective analysis 142
AISF position paper on HCV in immunocompromised patients 127
Pulmonary Arterial Hypertension in ALK Receptor Tyrosine Kinase–Positive Lung Cancer Patient: Adverse Event or Disease Spread? 112
Sensitivity to asbestos is increased in patients with mesothelioma and pathogenic germline variants in BAP1 or other DNA repair genes 108
SARS-CoV-2 Infection in Cancer Patients: A Picture of an Italian Onco-Covid Unit 104
Quality of life analysis in lung cancer: A systematic review of phase III trials published between 2012 and 2018 103
Surrogate Endpoints in Second-Line Trials of Targeted Agents in Metastatic Colorectal Cancer: A Literature-Based Systematic Review and Meta-Analysis 100
Osimertinib-induced Cardiac Dysfunction in EGFRMutated Lung Cancer: A Case Series of Five Patients 99
Novel lymphocyte-independent antitumor activity by PD-1 blocking antibody against PD-1+ chemoresistant lung cancer cells 96
DNA repair gene expression level in peripheral blood and tumour tissue from non-small cell lung cancer and head and neck squamous cell cancer patients. 95
A review of guidelines for lung cancer 93
Italian survey on the clinical management of non-small cell lung cancer patients during the COVID-19 pandemic: A lesson for the second wave 89
Clinical and molecular features of epidermal growth factor receptor (Egfr) mutation positive non‐small‐cell lung cancer (nsclc) patients treated with tyrosine kinase inhibitors (tkis): Predictive and prognostic role of co‐mutations 88
Immune-checkpoint inhibition in stage III unresectable NSCLC: Challenges and opportunities in the post-PACIFIC era 86
Evaluation of the preclinical efficacy of lurbinectedin in malignant pleural mesothelioma 86
Squamous carcinoma of the lung: Still a long and winding road to successful treatment 84
New emerging targets in cancer immunotherapy: The role of VISTA 84
Future perspectives from lung cancer pre-clinical models: new treatments are coming? 83
Five-year overall survival of pembrolizumab in advanced non-small cell lung cancer: another step from care to cure? 81
Differential influence of antibiotic therapy and other medications on oncological outcomes of patients with non-small cell lung cancer treated with first-line pembrolizumab versus cytotoxic chemotherapy 81
Pathological characterization of tumor immune microenvironment (Time) in malignant pleural mesothelioma 80
Malignant pleural mesothelioma: new guidelines make us stronger for defeating this disease 80
Neoadjuvant chemo-radiotherapy for locally advanced esophageal cancer: a monocentric study. 79
SKP2 drives the sensitivity to neddylation inhibitors and cisplatin in malignant pleural mesothelioma 78
Dealing with NSCLC EGFR mutation testing and treatment: a comprehensive review with an Italian real-world perspective 77
Chapter 17, Achievements in Targeted Therapies - ERS Monographs - Lung Cancer 76
Targeting kras in nsclc: Old failures and new options for “non-g12c” patients 76
A Prospective Phase II Single-arm Study of Niraparib Plus Dostarlimab in Patients With Advanced Non–small-cell Lung Cancer and/or Malignant Pleural Mesothelioma, Positive for PD-L1 Expression and Germline or Somatic Mutations in the DNA Repair Genes: Rationale and Study Design 75
Descriptive Comparative Analysis of Patients With Cancer Referring to the Emergency Department of an Italian University Hospital Across the Severe Acute Respiratory Syndrome Coronavirus 2 Waves 74
Repositioning PARP inhibitors in the treatment of thoracic malignancies 74
Strategies for managing ACTH dependent mineralocorticoid excess induced by abiraterone. 72
Is there any place for immune-checkpoint inhibitors in the treatment algorithm of fusion-driven non-small cell lung cancer?-a literature review 72
Predicting immunotherapy outcomes under therapy in patients with advanced NSCLC using dNLR and its early dynamics 72
DNA Methylation Profiling Discriminates between Malignant Pleural Mesothelioma and Neoplastic or Reactive Histologic Mimics 69
Deep learning using tumor HLA peptide mass spectrometry datasets improves neoantigen identification 65
Local for advanced, is this a paradox? 65
Exploring the role of respiratory microbiome in lung cancer: A systematic review 63
Major breakthroughs in lung cancer adjuvant treatment: Looking beyond the horizon 62
Comparing T Cell Subsets in Broncho-Alveolar Lavage (BAL) and Peripheral Blood in Patients with Advanced Lung Cancer 60
Clinical-Molecular Prospective Cohort Study in Non-Small Cell Lung Cancer (PROMOLE study): A Comprehensive Approach to Identify New Predictive Markers of Pharmacological Response 60
Oncological Procedures and Risk Assessment of COVID-19 in Thoracic Cancer Patients: A Picture From an Italian Cancer Center 60
Raising the bar for enthusiasm when looking at results of randomized phase II trials-The case of sunitinib in small-cell lung cancer 59
Immune checkpoint inhibitors a new player in the therapeutic game of mesothelioma: New reality with new challenges 58
Diagnostics of BAP1-Tumor Predisposition Syndrome by a Multitesting Approach: A Ten-Year-Long Experience 56
Emergency room comprehensive assessment of demographic, radiological, laboratory and clinical data of patients with COVID-19: determination of its prognostic value for in-hospital mortality 56
Pemetrexed, Vitamin B12, and Thoracic Tumors: The Times, They Are A-Changin’ 54
Oligoprogressive Disease With SCLC Transformation in EGFR-Mutated NSCLC: How Biology Knowledge Can Change the Game Rules 54
Autocrine 17-β-estradiol/estrogen receptor-α loop determines the response to immune-checkpoint inhibitors in non-small cell lung cancer 51
Micro-RNA-215 and -375 regulate thymidylate synthase protein expression in pleural mesothelioma and mediate epithelial to mesenchymal transition 51
Performing oncological procedures during COVID-19 outbreak: a picture from an Italian cancer center 50
Thymidine phosphorylase: The unforeseen driver in colorectal cancer treatment? 50
Role of Second Line Chemotherapy and New Target Treatment in Recurrent Mesothelioma 49
Single agent VS-6766 or VS-6766 plus defactinib in KRAS-mutant non-small-cell lung cancer: the RAMP-202 phase II trial 48
Squamous cell histological transformation in a lung adenocarcinoma patient (hyper) progressing upon immunotherapy 48
Thymidylate synthase drives the phenotypes of epithelial-to-mesenchymal transition in non-small cell lung cancer 47
REACTION: A phase II study of etoposide and cis/carboplatin with or without pembrolizumab in untreated extensive small cell lung cancer 47
Exploring circular MET RNA as a potential biomarker in tumors exhibiting high MET activity 46
Real-world retrospective study of KRAS mutations in advanced nonsmall cell lung cancer in the era of immunotherapy 44
Resistance to anaplastic lymphoma kinase inhibitors: Knowing the enemy is half the battle won 43
MET exon 14 mutation: Another actionable genomic variation in patients with advanced NSCLC 42
First-line immune-chemotherapy combination: the right strategy to fight squamous non-small-cell lung cancer?. 42
How to personalize perioperative chemotherapy in early non-small cell lung cancer? 41
Tumor plasticity and therapeutic resistance in oncogene-addicted non-small cell lung cancer: from preclinical observations to clinical implications 38
Immunohistochemistry with 3 different clones in anaplastic lymphoma kinase fluorescence in situ hybridization positive non-small-cell lung cancer with thymidylate synthase expression analysis: a multicentre, retrospective, Italian study 37
Consensus clustering methodology to improve molecular stratification of non-small cell lung cancer 36
Pathogenesis, clinical manifestations and management of immune checkpoint inhibitors toxicity 34
Clinical evidence and adverse event management update of patients with RET- rearranged advanced non-small-cell lung cancer (NSCLC) treated with pralsetinib 32
Exercise in lung Cancer, the healthcare providers opinion (E.C.H.O.): Results of the EORTC lung cancer Group (LCG) survey 31
Optimizing the clinical management of EGFR-mutant advanced non-small cell lung cancer: a literature review 31
Winds From the ORIENT: New Data to Inform RATIONAL Choice? 31
Immune Checkpoint Inhibitors and Opioids in Patients with Solid Tumours: Is Their Association Safe? A Systematic Literature Review 30
Niraparib plus Dostarlimab in Pleural Mesothelioma or Non-Small Cell Lung Cancer harboring HRR mutations: interim results of the UNITO-001 phase 2 prospective trial 30
Short-Term Safety and Psychosocial Impact of the BNT162b2 mRNA COVID-19 Vaccine in Cancer Patients-An Italian Single-Center Experience 30
Modern Stereotactic Radiotherapy for Brain Metastases from Lung Cancer: Current Trends and Future Perspectives Based on Integrated Translational Approaches 29
The role of germline mutations in thoracic malignancies: between myth and reality 29
Deciphering Lung Adenocarcinoma Heterogeneity: An Overview of Pathological and Clinical Features of Rare Subtypes 28
PD-1 receptor outside the main paradigm: tumour-intrinsic role and clinical implications for checkpoint blockade 28
An Italian Multicenter Perspective Harmonization Trial for the Assessment of MET Exon 14 Skipping Mutations in Standard Reference Samples 25
Sharing Experience with Anaplastic Lymphoma Kinase Tyrosine Kinase Inhibitors in Lung Cancer: An Italian Expert Panel Discussion 24
Immune Checkpoint Inhibitors in Patients With Cancer and Infection by Hepatitis B or C Virus: A Perspective Through the Results of a European Survey 24
Association between changes in thioredoxin reductase and other peripheral blood biomarkers with response to PD-1 inhibitor-based combination immunotherapy in non-small cell lung cancer: a retrospective study 22
Totale 12.329
Categoria #
all - tutte 38.764
article - articoli 0
book - libri 0
conference - conferenze 811
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 39.575


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2019/2020744 0 0 0 0 0 0 128 135 158 132 95 96
2020/20211.558 68 143 146 108 180 144 94 111 111 126 123 204
2021/20221.558 129 95 87 99 79 58 151 129 66 133 335 197
2022/20232.420 163 244 80 206 215 472 181 211 274 104 165 105
2023/20241.918 206 242 132 200 187 241 92 119 37 151 142 169
2024/20251.915 99 255 202 279 681 296 103 0 0 0 0 0
Totale 12.573